Why medical imaging innovators are racing for regulatory clearance
Share
- 4DMedical (ASX:4DX) secured Australian therapeutic approval for its non-contrast lung imaging software platform.
- The affected software providers operate with contrasting financial profiles, ranging from $5.9 million to $628 million in annual revenues.
- Securing government healthcare reimbursement and international commercial distribution models remains the primary strategy for the sector.
